相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Daniel Tobias Michaeli et al.
CARDIOVASCULAR DRUGS AND THERAPY (2023)
The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
Zanfina Ademi et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis
Ronen Arbel et al.
AMERICAN JOURNAL OF MEDICINE (2021)
Reduction in Revascularization With Icosapent Ethyl Insights From REDUCE-IT Revascularization Analyses
Benjamin E. Peterson et al.
CIRCULATION (2021)
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
Subodh Verma et al.
CIRCULATION (2021)
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Arjun Majithia et al.
CIRCULATION (2021)
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry
Fabien Picard et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Prakriti Gaba et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg et al.
EUROPEAN HEART JOURNAL (2021)
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg et al.
EUROPEAN HEART JOURNAL (2021)
REDUCE-IT USA Results From the 3146 Patients Randomized in the United States
Deepak L. Bhatt et al.
CIRCULATION (2020)
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease
Patricia G. Synnott et al.
Journal of Managed Care & Specialty Pharmacy (2020)
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES])
Nathan D. Wong et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014
Wenjun Fan et al.
CARDIOLOGY AND THERAPY (2020)
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Fabien Picard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
Wenjun Fan et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Deepak L. Bhatt et al.
CLINICAL CARDIOLOGY (2017)
The National Prevention Strategy: Leveraging Multiple Sectors to Improve Population Health
Boris D. Lushniak et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2015)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)